DX3-213B is a potent oxidative phosphorylation (OXPHOS) complex I (also known as NDUFS7) antagonist (IC50 = 3.6 nM). DX3-213B impairs ATP generation (IC50 = 11 nM) and inhibits the proliferation of MIA PaCa-2 cells (IC50 = 9 nM) in galactose-containing media.
In vivo
, DX3-213B significantly delays tumor growth in a syngeneic mouse model of pancreatic cancer. DX3-213B is orally bioavailable.
Caractéristiques techniques
| Marque | Tocris Bioscience |
|---|
| Réf. B-LABO | BL-RE-166052 |
|---|
| Réf. fabricant | 30040319 |
|---|
| Nom chimique ou matériau | (4,4-Difluoro-1-piperidinyl)[(3R)-1-[[4-[(1-methylethyl)sulfonyl]phenyl]sulfonyl]-3-piperidinyl]methanone |
|---|
| CAS | 2749555-66-4 |
|---|
| Quantité | 10 mg |
|---|
| Cible | Oxidative Phosphorylation Inhibitors |
|---|
| Formule moléculaire | C<sub>20</sub>H<sub>28</sub>F<sub>2</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub> |
|---|
| Pureté | 0.97 |
|---|
Une question, une configuration particulière ?
Contactez-nous pour un devis.
